University of Oslo Research Links Blood Proteins to Coeliac Disease

Blood proteins may offer new clues to gut health in coeliac disease, according to research from the University of Oslo. Jostein Holen Ibsen, a PhD fellow and physician at the Norwegian Coeliac Disease Research Centre at the University of Oslo and the Clinical and Translational Coeliac Disease Centre at Oslo University Hospital, points out the core diagnostic challenge facing patients adhering to strict treatment regimens: Many people with coeliac disease are very diligent in following the diet, but they still live with uncertainty because the blood tests do not always give clear answers about how the disease is progressing.

Proteomic Analysis of 264 Samples at Rikshospitalet

To investigate whether circulating proteins can serve as reliable biomarkers of disease activity, Ibsen and colleagues examined 264 blood and tissue samples. The dataset included specimens gathered from individuals with coeliac disease both before treatment and after completing one year on a gluten-free diet, alongside samples from healthy control participants without the condition. All biological samples were collected at Rikshospitalet between 2018 and 2024 under formal patient research consent.

Using proteomics to scan large panels of proteins simultaneously, the research team isolated 24 specific proteins associated with coeliac disease. Among these, nine proteins showed a direct correlation with the severity of intestinal mucosal damage. Ibsen notes the distinct baseline divergence observed during the analysis: For many of the proteins, we found a clear difference between people with untreated coeliac disease and healthy individuals. Untreated patients exhibited the highest concentrations of inflammatory mediators, whereas healthy controls registered the lowest.

Limitations of Standard Anti-tTG IgA Testing Protocols

Clinical management of coeliac disease typically relies on initial diagnostic screening via blood tests measuring anti-tTG IgA antibodies and total IgA levels, accompanied by a confirmatory gastroscopy with small intestinal tissue biopsies. Following diagnosis, primary care physicians routinely monitor patients using the same antibody serology. However, this standard diagnostic framework loses precision once dietary intervention begins.

The problem with this blood test is that it simply does not work as well once patients have started treatment with a gluten-free diet, Ibsen explains. We have research showing that it can be somewhat misleading about what is actually happening in the gut.

While protein profiles shifted significantly toward normal ranges after one year of avoiding gluten, patients adhering to the diet maintained slightly elevated levels of specific proteins compared to the healthy control group. According to the researchers, this indicates lingering low-grade mucosal inflammation despite strict dietary compliance. Knut E. A. Lundin, Professor at the University of Oslo, notes that tests based on these new biomarkers could eventually augment current serology, which fails to cleanly differentiate between active intestinal injury and tissue healing.

Researchers Seek to Validate Biomarkers in Larger Cohorts

Translating these proteomic discoveries into routine clinical practice requires further investigation. The research team emphasizes that subsequent studies must validate the findings in larger patient cohorts and isolate the specific biomarker proteins holding the highest predictive value for disease monitoring.

Ibsen acknowledges the vital role of study participants in enabling the proteomic discovery phase, stating that patient contributions were indispensable for securing and analyzing the 264 biological samples.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.